Skip to main content

Advertisement

Log in

A systematic review and meta-analysis on the use of traditional Chinese medicine compound kushen injection for bone cancer pain

  • Review Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Purpose

Bone cancer pain presents a clinical challenge with limitations of current treatments. Compound kushen injection (CKI) is a well-known traditional Chinese medicine (TCM) formulation in treatment of patients with bone cancer pain. The objective of this study is to assess the efficacy and safety of CKI for bone cancer pain.

Methods

A systematic literature search was conducted in nine databases until December 2012 to identify randomized controlled trials (RCTs) of CKI versus current western therapies for bone cancer pain. The primary outcome was total pain relief rate. The secondary outcomes were the quality of life and adverse events at the end of treatment course. The methodological quality of RCTs was assessed independently using six-item criteria according to the Cochrane Collaboration, and the level of evidence was assessed by the GRADE approach. All data were analyzed using Review Manager 5.1.0.

Results

Seven RCTs with 521 patients from 2010 to 2012 were identified. Compared with radiotherapy or bisphosphonates, seven RCTs showed significant effects of CKI for improving pain relief in patients with bone cancer pain (n = 521, risk ratio (RR) = 1.25, 95 % CI (95 % confidence intervals (CI)), 1.13 to 1.38, p < 0.0001)), three RCTs for improving Karnofsky scoring (KPS) increase rate (n = 305, RR = 1.62, 95 % CI, 1.32 to 1.99, p < 0.00001), 1 RCT for increasing KPS scores (n = 78, mean difference (MD) = 10.43, 95 % CI 4.76 to 16.10, p = 0.0003). 4 RCTs reported adverse effects in both the treatment and control groups. The patients treated with CKI achieved statistically significant reductions of incidences of leukopenia (n = 276, RR = 0.32, 95 % CI, 0.21 to 0.47, p < 0.00001) and nausea (n = 78, RR = 0.15, 95 % CI, 0.06 to 0.34, p < 0.00001). No severe adverse events were found and no treatment was stopped because of adverse events of CKI in the treatment groups. However, the studies were deemed to have a high risk of bias.

Conclusion

This systematic review showed positive but weak evidence of CKI for bone cancer pain because of the poor methodological quality and the small quantity of the included trials. Future rigorously designed RCTs are required.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Thurlimann B, de Stoutz ND (1996) Causes and treatment of bone pain of malignant origin. Drugs 51:383–398

    Article  CAS  PubMed  Google Scholar 

  2. Peters CM, Ghilardi JR, Keyser CP, Kubota K, Lindsay TH, Luger NM, Mach DB, Schwei MJ, Sevcik MA, Mantyh PW (2005) Tumor-induced injury of primary afferent sensory nerve fibers in bone cancer pain. Exp Neurol 193:85–100

    Article  PubMed  Google Scholar 

  3. Portenoy RKFK, Lussier D, Hanks G (2004) Difficult pain problems: an integrated approach. Oxford University Press, Oxford

    Google Scholar 

  4. Colvin L, Fallon M (2008) Challenges in cancer pain management—bone pain. Eur J Cancer 44:1083–1090, Oxford, England: 1990

    Article  CAS  PubMed  Google Scholar 

  5. Mercadante S, Arcuri E (1998) Breakthrough pain in cancer patients: pathophysiology and treatment. Cancer Treat Rev 24:425–432

    Article  CAS  PubMed  Google Scholar 

  6. Laird BJ WJ, Murray G (2009) What is the key question in the assessment of cancer induced bone pain: results from a characterization study. British Pain Society, London

  7. de Wit R, van Dam F, Loonstra S, Zandbelt L, van Buuren A, van der Heijden K, Leenhouts G, Huijer Abu-Saad H (2001) The Amsterdam Pain Management Index compared to eight frequently used outcome measures to evaluate the adequacy of pain treatment in cancer patients with chronic pain. Pain 91:339–349

    Article  PubMed  Google Scholar 

  8. Meuser T, Pietruck C, Radbruch L, Stute P, Lehmann KA, Grond S (2001) Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. Pain 93:247–257

    Article  CAS  PubMed  Google Scholar 

  9. Mercadante S (1997) Malignant bone pain: pathophysiology and treatment. Pain 69:1–18

    Article  CAS  PubMed  Google Scholar 

  10. Rubens RD (1998) Bone metastases—the clinical problem. Eur J Cancer 34:210–213, Oxford, England: 1990

    Article  CAS  PubMed  Google Scholar 

  11. Chow E, Zeng L, Salvo N, Dennis K, Tsao M, Lutz S (2012) Update on the systematic review of palliative radiotherapy trials for bone metastases. Clin Oncol 24:112–124

    Article  CAS  Google Scholar 

  12. McQuay HJ, Collins SL, Carroll D, Moore RA (2000) Radiotherapy for the palliation of painful bone metastases. The Cochrane database of systematic reviews: CD001793

  13. Bailey FFA (2006) Oral opioid drugs. Oxford University Press, Oxford

    Google Scholar 

  14. Portenoy RK, Payne D, Jacobsen P (1999) Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 81:129–134

    Article  CAS  PubMed  Google Scholar 

  15. Chan FK (2006) Primer: managing NSAID-induced ulcer complications—balancing gastrointestinal and cardiovascular risks. Nat Clin Pract Gastroenterol Hepatol 3:563–573

    Article  CAS  PubMed  Google Scholar 

  16. Lapeyre-Mestre M, de Castro AM, Bareille MP, Del Pozo JG, Requejo AA, Arias LM, Montastruc JL, Carvajal A (2006) Non-steroidal anti-inflammatory drug-related hepatic damage in France and Spain: analysis from national spontaneous reporting systems. Fundam Clin Pharmacol 20:391–395

    Article  CAS  PubMed  Google Scholar 

  17. Schaffer D, Florin T, Eagle C, Marschner I, Singh G, Grobler M, Fenn C, Schou M, Curnow KM (2006) Risk of serious NSAID-related gastrointestinal events during long-term exposure: a systematic review. Med J Aust 185:501–506

    PubMed  Google Scholar 

  18. Schneider V, Levesque LE, Zhang B, Hutchinson T, Brophy JM (2006) Association of selective and conventional nonsteroidal antiinflammatory drugs with acute renal failure: a population-based, nested case–control analysis. Am J Epidemiol 164:881–889

    Article  PubMed  Google Scholar 

  19. Michaelson MD, Smith MR (2005) Bisphosphonates for treatment and prevention of bone metastases. J Clin Oncol Off J Am Soc Clin Oncol 23:8219–8224

    Article  CAS  Google Scholar 

  20. Wong R, Wiffen PJ (2002) Bisphosphonates for the relief of pain secondary to bone metastases. The Cochrane database of systematic reviews. CD002068

  21. Chen YZLP (2005) Effectiveness and application of Chinese medicine for cancer pain. Clin J Tradit Chin Med 17:529–531

    Google Scholar 

  22. Tian JWW, Gao HM, Wang ZM (2007) Determination of matrine, sophoridine and oxymatrine in compound kushen injection by HPLC. Zhongguo Zhong Yao Za Zhi 32:222–224

    CAS  PubMed  Google Scholar 

  23. Luo XYZX, Gao W (2001) Studies on site of analgesic action of matrine and its mechanism. Chin Tradit Herb Drugs 32:41–43

    CAS  Google Scholar 

  24. Cao WLBJ, Guo RY (2012) Radiotherapy combined with compound kushen injection in the treatment for 58 cases with malignant bone metastasis. Chin Remedies Clin 12:1217–1218

    Google Scholar 

  25. LA Chen G, Gu HG, Lu Y, Wang X, Zhang SK (2010) Clinical analysis of treating metastatic bone cancer with radiotherapy plus compound kushen injection. China Med Eng 18:48–50

    Google Scholar 

  26. Ge CZXY, Zhang DF (2011) Clinical observation of compound kushen injection combined with three-dimensional conformal radiotherapy for advanced metastatic bone pain. Shandong Med J 51:72–73

    Google Scholar 

  27. Ren FFY, Li SD, Lin MX, Wang HM, Li M (2012) Efficacy and safety of compound kushen injection combined with zoledronic acid for ostealgia in patients with malignant tumor and osseous metastases. Eval Anal Drug-Use Hosp China 12:246–248

    Google Scholar 

  28. Ren SPLJ, Zheng YS (2011) Radiotherapy combined with compound matrine injection in the treatment for 30 cases with malignant bone metastasis. J Chin Oncol 17:795–796

    Google Scholar 

  29. Wang RYM, Pan XY (2011) Clinical observation of compound matrine injection combined with radiotherapy for advanced metastatic bone pain. China Pharm 22:329–331

    Google Scholar 

  30. Zhang YKLB, Zhu XZ (2011) Clinical observation of compound kushen injection combined with radiotherapy for advanced metastatic bone pain. Shandong Med J 51:84–85

    CAS  Google Scholar 

  31. Chan K, Shaw D, Simmonds MS, Leon CJ, Xu Q, Lu A, Sutherland I, Ignatova S, Zhu YP, Verpoorte R, Williamson EM, Duez P (2012) Good practice in reviewing and publishing studies on herbal medicine, with special emphasis on traditional Chinese medicine and Chinese materia medica. J Ethnopharmacol 140:469–475

    Article  PubMed  Google Scholar 

  32. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097

    Article  PubMed Central  PubMed  Google Scholar 

  33. WHO (1996) Cancer pain relief. 2nd edn. World Health Organization, Geneva, pp. 1–8

  34. Balshem H, Helfand M, Schunemann HJ, Oxman AD, Kunz R, Brozek J, Vist GE, Falck-Ytter Y, Meerpohl J, Norris S, Guyatt GH (2011) GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol 64:401–406

    Article  PubMed  Google Scholar 

  35. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, Norris S, Falck-Ytter Y, Glasziou P, DeBeer H, Jaeschke R, Rind D, Meerpohl J, Dahm P, Schunemann HJ (2011) GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 64:383–394

    Article  PubMed  Google Scholar 

  36. Guyatt GH, Oxman AD, Kunz R, Atkins D, Brozek J, Vist G, Alderson P, Glasziou P, Falck-Ytter Y, Schunemann HJ (2011) GRADE guidelines: 2. Framing the question and deciding on important outcomes. J Clin Epidemiol 64:395–400

    Article  PubMed  Google Scholar 

  37. Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P, Montori V, Akl EA, Djulbegovic B, Falck-Ytter Y, Norris SL, Williams JW Jr, Atkins D, Meerpohl J, Schunemann HJ (2011) GRADE guidelines: 4. Rating the quality of evidence–study limitations (risk of bias). J Clin Epidemiol 64:407–415

    Article  PubMed  Google Scholar 

  38. Review Manager (RevMan) [Computer program] VfW (2008). In: Editor (ed)^(eds) Book. The Nordic Cochrane Centre, City

  39. Chen A, Muzzio IA, Malleret G, Bartsch D, Verbitsky M, Pavlidis P, Yonan AL, Vronskaya S, Grody MB, Cepeda I, Gilliam TC, Kandel ER (2003) Inducible enhancement of memory storage and synaptic plasticity in transgenic mice expressing an inhibitor of ATF4 (CREB-2) and C/EBP proteins. Neuron 39:655–669

    Article  CAS  PubMed  Google Scholar 

  40. Wang LN, Yao M, Yang JP, Peng J, Peng Y, Li CF, Zhang YB, Ji FH, Cheng H, Xu QN, Wang XY, Zuo JL (2011) Cancer-induced bone pain sequentially activates the ERK/MAPK pathway in different cell types in the rat spinal cord. Mol Pain 7:48

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  41. Song XS, Cao JL, Xu YB, He JH, Zhang LC, Zeng YM (2005) Activation of ERK/CREB pathway in spinal cord contributes to chronic constrictive injury-induced neuropathic pain in rats. Acta Pharmacol Sin 26:789–798

    Article  CAS  PubMed  Google Scholar 

  42. Zhang K, Li YJ, Yang Q, Gerile O, Yang L, Li XB, Guo YY, Zhang N, Feng B, Liu SB, Zhao MG (2013) Neuroprotective effects of oxymatrine against excitotoxicity partially through down-regulation of NR2B-containing NMDA receptors. Phytomedicine Int J Phytother Phytopharmacol 20:343–350

    Article  CAS  Google Scholar 

  43. Wang H, Li Y, Dun L, Xu Y, Jin S, Du J, Ma L, Li J, Zhou R, He X, Sun T, Yu J (2013) Antinociceptive effects of oxymatrine from Sophora flavescens, through regulation of NR2B-containing NMDA receptor-ERK/CREB signaling in a mice model of neuropathic pain. Phytomedicine : Int J Phytother Phytopharmacol 20:1039–1045

    Article  CAS  Google Scholar 

  44. De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, Kotzin S, Laine C, Marusic A, Overbeke AJ, Schroeder TV, Sox HC, Van Der Weyden MB, International Committee of Medical Journal Editors (2004) Clinical trial registration: a statement from the International Committee of Medical Journal Editors. New England J Med 351:1250–1251

    Article  Google Scholar 

  45. Ernst E, Lee MS (2008) A trial design that generates only ''positive'' results. J Postgrad Med 54:214–216

    Article  CAS  PubMed  Google Scholar 

  46. De Smet PA (2002) Herbal remedies. New England J Med 347:2046–2056

    Article  Google Scholar 

  47. Vickers A, Goyal N, Harland R, Rees R (1998) Do certain countries produce only positive results? A systematic review of controlled trials. Control Clin trials 19:159–166

    Article  CAS  PubMed  Google Scholar 

  48. Caraceni A, Brunelli C, Martini C, Zecca E, De Conno F (2005) Cancer pain assessment in clinical trials. A review of the literature (1999–2002). J Pain Sympt Manag 29:507–519

    Article  Google Scholar 

  49. Carr DB, Goudas LC, Balk EM, Bloch R, Ioannidis JP, Lau J (2004) Evidence report on the treatment of pain in cancer patients. J Natl Cancer Inst Monogr 23–31

  50. Kaasa S (2008) Palliative care research: time to intensify international collaboration. Palliat Med 22:301–302

    Article  CAS  PubMed  Google Scholar 

  51. Schulz KF, Altman DG, Moher D, CONSORT Group (2010) CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Med 7:e1000251

    Article  PubMed Central  PubMed  Google Scholar 

  52. Calvert M, Blazeby J, Altman DG, Revicki DA, Moher D, Brundage MD, CONSORT PRO Group (2013) Reporting of patient-reported outcomes in randomized trials: the CONSORT PRO extension. JAMA : J Am Med Assoc 309:814–822

    Article  CAS  Google Scholar 

  53. Flower A, Witt C, Liu JP, Ulrich-Merzenich G, Yu H, Lewith G (2012) Guidelines for randomised controlled trials investigating Chinese herbal medicine. J Ethnopharmacol 140:550–554

    Article  PubMed  Google Scholar 

  54. Bian Z, Liu B, Moher D, Wu T, Li Y, Shang H, Cheng C (2011) Consolidated standards of reporting trials (CONSORT) for traditional Chinese medicine: current situation and future development. Front Med 5:171–177

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

The current work was partially supported by the National Natural Science Foundation Project of China (no. 81273718 and no. 81302961). The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the paper. The authors declare no conflict of interest.

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Bao Yanju, Baojin Hua or Wei Hou.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yanju, B., Yang, L., Hua, B. et al. A systematic review and meta-analysis on the use of traditional Chinese medicine compound kushen injection for bone cancer pain. Support Care Cancer 22, 825–836 (2014). https://doi.org/10.1007/s00520-013-2063-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-013-2063-5

Keywords

Navigation